Acridine carboxamide: Difference between revisions

Jump to navigation Jump to search
m (Protected "Acridine carboxamide": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
 
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
 
Line 1: Line 1:
{{SI}}
{{SI}}
{{EH}}
 


==Overview==
==Overview==
Line 9: Line 9:
==References==
==References==
<references/>
<references/>
{{SIB}}
 
[[Category:Chemotherapeutic agents]]
[[Category:Chemotherapeutic agents]]
{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WS}}
{{WS}}

Latest revision as of 20:37, 8 August 2012

WikiDoc Resources for Acridine carboxamide

Articles

Most recent articles on Acridine carboxamide

Most cited articles on Acridine carboxamide

Review articles on Acridine carboxamide

Articles on Acridine carboxamide in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Acridine carboxamide

Images of Acridine carboxamide

Photos of Acridine carboxamide

Podcasts & MP3s on Acridine carboxamide

Videos on Acridine carboxamide

Evidence Based Medicine

Cochrane Collaboration on Acridine carboxamide

Bandolier on Acridine carboxamide

TRIP on Acridine carboxamide

Clinical Trials

Ongoing Trials on Acridine carboxamide at Clinical Trials.gov

Trial results on Acridine carboxamide

Clinical Trials on Acridine carboxamide at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Acridine carboxamide

NICE Guidance on Acridine carboxamide

NHS PRODIGY Guidance

FDA on Acridine carboxamide

CDC on Acridine carboxamide

Books

Books on Acridine carboxamide

News

Acridine carboxamide in the news

Be alerted to news on Acridine carboxamide

News trends on Acridine carboxamide

Commentary

Blogs on Acridine carboxamide

Definitions

Definitions of Acridine carboxamide

Patient Resources / Community

Patient resources on Acridine carboxamide

Discussion groups on Acridine carboxamide

Patient Handouts on Acridine carboxamide

Directions to Hospitals Treating Acridine carboxamide

Risk calculators and risk factors for Acridine carboxamide

Healthcare Provider Resources

Symptoms of Acridine carboxamide

Causes & Risk Factors for Acridine carboxamide

Diagnostic studies for Acridine carboxamide

Treatment of Acridine carboxamide

Continuing Medical Education (CME)

CME Programs on Acridine carboxamide

International

Acridine carboxamide en Espanol

Acridine carboxamide en Francais

Business

Acridine carboxamide in the Marketplace

Patents on Acridine carboxamide

Experimental / Informatics

List of terms related to Acridine carboxamide


Overview

Acridine carboxamide (N-[(2'-dimethylamino)ethyl]acridine-4-carboxamide) is an chemotherapy agent that is being studied in the treatment of cancer. It belongs to the family of drugs called topoisomerase inhibitors.

While the agent was well-tolerated in Phase II clinical trials, it did not show efficacy when tested against various types of cancers.[1][2][3][4]

References

  1. Dittrich C, Dieras V, Kerbrat P; et al. (2003). "Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer". Investigational new drugs. 21 (3): 347–52. PMID 14578683.
  2. Caponigro F, Dittrich C, Sorensen JB; et al. (2002). "Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer". Eur. J. Cancer. 38 (1): 70–4. PMID 11750842.
  3. Twelves C, Campone M, Coudert B; et al. (2002). "Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme". Ann. Oncol. 13 (5): 777–80. PMID 12075748.
  4. Dittrich C, Coudert B, Paz-Ares L; et al. (2003). "Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer". Eur. J. Cancer. 39 (3): 330–4. PMID 12565985.

Template:WS